Daily Updates on Generic Entry, Litigation, Biosimilars, and more …
Want insights into the biggest revenue-changing events?
Billions of dollars in sales can evaporate overnight as drug patents expire and competitors enter the market.
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants
Completed
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Phase 1
1969-12-31
The purpose of this study is to see if giving nelfinavir (NFV) plus zidovudine (ZDV) plus
lamivudine (3TC) to HIV-positive pregnant women and their babies is safe. This study will
also look at how long these drugs stay in the blood.
ZDV has been given to mothers in the past to reduce the chances of passing HIV on to their
babies. However, better treatments are needed to further reduce these chances and to better
suit the treatment needs of mothers and their children. Taking a combination of anti-HIV
drugs during pregnancy may be an answer.
A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants
Completed
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 1
1969-12-31
The purpose of this study is to see if giving nelfinavir (NFV) plus zidovudine (ZDV) plus
lamivudine (3TC) to HIV-positive pregnant women and their babies is safe. This study will
also look at how long these drugs stay in the blood.
ZDV has been given to mothers in the past to reduce the chances of passing HIV on to their
babies. However, better treatments are needed to further reduce these chances and to better
suit the treatment needs of mothers and their children. Taking a combination of anti-HIV
drugs during pregnancy may be an answer.
Phase I Study of Safety, Tolerability, and Pharmacokinetics of Viracept in HIV-1 Infected Children and Exposed Infants
Completed
Agouron Pharmaceuticals
Phase 1
1969-12-31
To evaluate the single dose pharmacokinetic profile of Viracept pediatric powder formulation
administered to HIV infected or exposed children and infants (0 to 13 years of age). An
evaluation of the relative bioavailability of the pediatric powder formulation vs. a
standard tablet formulation in older children (7 to 13 years of age) will also be conducted.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
